Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial

Study point of contact

James R Young, MD
704-578-5078
[email protected]

Locations

1 Cameroon site

1 Tanzania site

Age

4 to 16 Years

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Drug

Other

Compensation

Unknown

About the study

The purpose of this study is to determine if the use of ketamine, sniffed in the nose, is a
safe and effective way to help reduce pain in pediatric sickle cell patients with pain crises
in resource-limited settings.

participation requirements

– Sickle cell disease (SCD)

– Vasoocclusive pain crisis

– Requiring analgesia

participation restrictions

– Anatomic variations of nose precluding intranasal medication administration

– Ketamine allergy

– Non-verbal

– Obtunded

– Pregnant

– Other acute SCD complications:

– Acute chest syndrome

– Sepsis

– Stroke

– Splenic sequestration

– Pulmonary embolism

– Acute osteomyelitis

Locations

  • Bamenda, Northwest Province, Cameroon, Mbingo Baptist Hospital [Recruiting]
  • Dar es Salam, Tanzania, Muhimbili National Hospital [Not yet recruiting]